The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review
Open accessAbstract
Objective: To update evidence‐based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD). Background: The International Parkinson and Movement Disorder Society Evidence‐Based Medicine Committee's recommendations for treatments of PD were first published in 2002, updated in 2011, and now updated again through December 31, 2016. Methods: Level I studies testing pharmacological, surgical, or nonpharmacological interventions for the treatment of nonmotor symptoms in PD were reviewed. Criteria for inclusion and quality scoring were as previously reported. The disorders covered were a range of neuropsychiatric symptoms, autonomic dysfunction, disorders of sleep and wakefulness, pain, fatigue, impaired olfaction, and ophthalmologic dysfunction. Clinical efficacy, implications for clinical practice, and safety conclusions are reported. Results: A total of 37 new studies qualified for review. There were no randomized controlled trials that met inclusion criteria for the treatment of anxiety disorders, rapid eye movement sleep behavior disorder, excessive sweating, impaired olfaction, or ophthalmologic dysfunction. We identified clinically useful or possibly useful interventions for the treatment of depression, apathy, impulse control and related disorders, dementia, psychosis, insomnia, daytime sleepiness, drooling, orthostatic hypotension, gastrointestinal dysfunction, urinary dysfunction, erectile dysfunction, fatigue, and pain. There were no clinically useful interventions identified to treat non‐dementia‐level cognitive impairment. Conclusions: The evidence base for treating a range of nonmotor symptoms in PD has grown substantially in recent years. However, treatment options overall remain limited given the high prevalence and adverse impact of these disorders, so the development and testing of new treatments for nonmotor symptoms in PD remains a top priority. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Self-citationCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Weaver, F. M. (2009) · JAMA · doi:10.1001/jama.2008.929 · Cited by 1,525
Neurostimulation for Parkinson's Disease with Early Motor Complications
Schuepbach, W. M. M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T. D., Hesekamp, H., Navarro, S. M., Meier, N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205158 · Cited by 1,430
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Self-citationFox, S. H., Katzenschlager, R., Lim, S., Barton, B., de Bie, R. M. A., Seppi, K., Coelho, M., Sampaio, C., & on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee (2018) · Movement Disorders · doi:10.1002/mds.27372 · Cited by 1,002
Self-citationCummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., Dhall, R., & Ballard, C. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62106-6 · Cited by 954
Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review
Mitchell, M. D., Gehrman, P., Perlis, M., & Umscheid, C. A. (2012) · BMC Family Practice · doi:10.1186/1471-2296-13-40 · Cited by 617 · cited 1×
“” In general, reporting of adverse events (AEs) in CBT trials is limited (Table 2).(85,86) Therefore, there is “insufficient evidence” to conclude on the safety of CBT in PD patients with depression.”
BackgroundBarone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., & Weintraub, D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70106-x · Cited by 562
Self-citationEbell, M. H., Siwek, J., Weiss, B. D., Woolf, S. H., Susman, J., Ewigman, B., & Bowman, M. (2004) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.17.1.59 · Cited by 561
Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment
Pagonabarraga, J., Kulisevsky, J., Strafella, A. P., & Krack, P. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00019-8 · Cited by 549
Neuropathic Pain: Principles of Diagnosis and Treatment
Gilron, I., Baron, R., & Jensen, T. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.01.018 · Cited by 540
Fox, S. H., Katzenschlager, R., Lim, S., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C. G., & Sampaio, C. (2011) · Movement Disorders · doi:10.1002/mds.23829 · Cited by 523
Self-citationEbell, M. H., Siwek, J., Weiss, B. D., Woolf, S. H., Susman, J. L., Ewigman, B., & Bowman, M. A. (2004) · PubMed · Cited by 484
Olfaction in Parkinson's disease and related disorders
Doty, R. L. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.026 · Cited by 431
Chaudhuri, K. R., Prieto‐Jurcynska, C., Naidu, Y., Mitra, T., Frades‐Payo, B., Tluk, S., Ruessmann, A., Odin, P., Macphee, G., Stocchi, F., et al. (2010) · Movement Disorders · doi:10.1002/mds.22868 · Cited by 431
A controlled trial of antidepressants in patients with Parkinson disease and depression
Menza, M., Dobkin, R. D., Marin, H., Mark, M. H., Gara, M., Buyske, S., Bienfait, K., & Dicke, A. (2009) · Neurology · doi:10.1212/01.wnl.0000336340.89821.b3 · Cited by 414
Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT
Barichella, M., Pacchetti, C., Bolliri, C., Cassani, E., Iorio, L., Pusani, C., Pinelli, G., Privitera, G., Cesari, I., Faierman, S. A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003127 · Cited by 390
Pompeu, J. E., Mendes, F. A. D. S., Silva, K. G. D., Lobo, A. M., Oliveira, T. D. P., Zomignani, A. P., & Piemonte, M. E. P. (2012) · Physiotherapy · doi:10.1016/j.physio.2012.06.004 · Cited by 354
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
Richard, I. H., McDermott, M. P., Kurlan, R., Lyness, J. M., Como, P. G., Pearson, N., Factor, S. A., Juncos, J., Serrano Ramos, C., Brodsky, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182516244 · Cited by 338
Motivation, reward, and Parkinson's disease: influence of dopatherapy
Czernecki, V (2002) · Neuropsychologia · doi:10.1016/s0028-3932(02)00108-2 · Cited by 338
Clinical spectrum of impulse control disorders in Parkinson’s disease
Weintraub, D., David, A. S., Evans, A. H., Grant, J. E., & Stacy, M. (2015) · Movement Disorders · doi:10.1002/mds.26016 · Cited by 311
Self-citationCognitive-Behavioral Therapy for Depression in Parkinson's Disease: A Randomized, Controlled Trial
Dobkin, R. D., Menza, M., Allen, L. A., Gara, M. A., Mark, M. H., Tiu, J., Bienfait, K. L., & Friedman, J. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111669 · Cited by 310
Burn, D., Emre, M., McKeith, I., De Deyn, P. P., Aarsland, D., Hsu, C., & Lane, R. (2006) · Movement Disorders · doi:10.1002/mds.21077 · Cited by 310
Cognitive training in Parkinson disease: A systematic review and meta-analysis
Leung, I. H. K., Walton, C. C., Hallock, H., Lewis, S. J. G., Valenzuela, M., & Lampit, A. (2015) · Neurology · doi:10.1212/wnl.0000000000002145 · Cited by 309
Caffeine for treatment of Parkinson disease: A randomized controlled trial
Postuma, R. B., Lang, A. E., Munhoz, R. P., Charland, K., Pelletier, A., Moscovich, M., Filla, L., Zanatta, D., Rios Romenets, S., Altman, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318263570d · Cited by 298
Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours
Lhommée, E., Klinger, H., Thobois, S., Schmitt, E., Ardouin, C., Bichon, A., Kistner, A., Fraix, V., Xie, J., Aya Kombo, M., et al. (2012) · Brain · doi:10.1093/brain/aws078 · Cited by 296
Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., & Friedman, J. H. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.176 · Cited by 292
The expanding evidence base for rTMS treatment of depression
George, M. S., Taylor, J. J., & Short, E. B. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835ab46d · Cited by 288
Sherman, D. S., Mauser, J., Nuno, M., & Sherzai, D. (2017) · Neuropsychology Review · doi:10.1007/s11065-017-9363-3 · Cited by 281
Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil
Thobois, S., Lhommée, E., Klinger, H., Ardouin, C., Schmitt, E., Bichon, A., Kistner, A., Castrioto, A., Xie, J., Fraix, V., et al. (2013) · Brain · doi:10.1093/brain/awt067 · Cited by 274
Olfactory Dysfunction in Neurodegenerative Diseases
Marin, C., Vilas, D., Langdon, C., Alobid, I., López-Chacón, M., Haehner, A., Hummel, T., & Mullol, J. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0796-4 · Cited by 274
Wang, H.-F., Yu, J.-T., Tang, S.-W., Jiang, T., Tan, C.-C., Meng, X.-F., Wang, C., Tan, M.-S., & Tan, L. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307659 · Cited by 269
Ehrt, U., Broich, K., Larsen, J. P., Ballard, C., & Aarsland, D. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.186239 · Cited by 254
Martinez‐Martin, P., Reddy, P., Katzenschlager, R., Antonini, A., Todorova, A., Odin, P., Henriksen, T., Martin, A., Calandrella, D., Rizos, A., et al. (2015) · Movement Disorders · doi:10.1002/mds.26067 · Cited by 247
Self-citationTreatment of autonomic dysfunction in Parkinson disease and other synucleinopathies
Palma, J., & Kaufmann, H. (2018) · Movement Disorders · doi:10.1002/mds.27344 · Cited by 245
Parkinson’s: a syndrome rather than a disease?
Titova, N., Padmakumar, C., Lewis, S. J. G., & Chaudhuri, K. R. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-016-1667-6 · Cited by 233
Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting
Uc, E. Y., Doerschug, K. C., Magnotta, V., Dawson, J. D., Thomsen, T. R., Kline, J. N., Rizzo, M., Newman, S. R., Mehta, S., Grabowski, T. J., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000644 · Cited by 230
Apathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom
Czernecki, V., Schüpbach, M., Yaici, S., Lévy, R., Bardinet, E., Yelnik, J., Dubois, B., & Agid, Y. (2008) · Movement Disorders · doi:10.1002/mds.21949 · Cited by 230
Psychosis, apathy, depression and anxiety in Parkinson's disease
Gallagher, D. A., & Schrag, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.041 · Cited by 211
Witt, K., Granert, O., Daniels, C., Volkmann, J., Falk, D., van Eimeren, T., & Deuschl, G. (2013) · Brain · doi:10.1093/brain/awt151 · Cited by 211
Atypical Antipsychotic Use in Patients With Dementia: Managing Safety Concerns
Steinberg, M., & Lyketsos, C. G. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12030342 · Cited by 209
Tricco, A. C., Soobiah, C., Berliner, S., Ho, J. M., Ng, C. H., Ashoor, H. M., Chen, M. H., Hemmelgarn, B., & Straus, S. E. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.130451 · Cited by 209
Recognition and Treatment of Depression in Parkinson's Disease
Weintraub, D., Moberg, P. J., Duda, J. E., Katz, I. R., & Stern, M. B. (2003) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988703256053 · Cited by 208
Self-citationTrial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers
Okai, D., Askey-Jones, S., Samuel, M., O’Sullivan, S. S., Chaudhuri, K. R., Martin, A., Mack, J., Brown, R. G., & David, A. S. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840678 · Cited by 202
Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study
Dubois, B., Tolosa, E., Katzenschlager, R., Emre, M., Lees, A. J., Schumann, G., Pourcher, E., Gray, J., Thomas, G., Swartz, J., et al. (2012) · Movement Disorders · doi:10.1002/mds.25098 · Cited by 202
Self-citationDevos, D., Moreau, C., Maltete, D., Lefaucheur, R., Kreisler, A., Eusebio, A., Defer, G., Ouk, T., Azulay, J.-P., Krystkowiak, P., et al. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306439 · Cited by 199
Effects of tDCS on executive function in Parkinson's disease
Doruk, D., Gray, Z., Bravo, G. L., Pascual-Leone, A., & Fregni, F. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.08.043 · Cited by 194
Management of Parkinson's disease: An evidence-based review
Lang, A. E., & Lees, A. (2002) · Movement Disorders · doi:10.1002/mds.5554 · Cited by 184
Hashimoto, H., Takabatake, S., Miyaguchi, H., Nakanishi, H., & Naitou, Y. (2015) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2015.01.010 · Cited by 181
Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial
Brys, M., Fox, M. D., Agarwal, S., Biagioni, M., Dacpano, G., Kumar, P., Pirraglia, E., Chen, R., Wu, A., Fernandez, H., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003279 · Cited by 180
Lee, N.-Y., Lee, D.-K., & Song, H.-S. (2015) · Journal of Physical Therapy Science · doi:10.1589/jpts.27.145 · Cited by 179
REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies
St Louis, E. K., Boeve, A. R., & Boeve, B. F. (2017) · Movement Disorders · doi:10.1002/mds.27018 · Cited by 171
A survey of antidepressant drug use in Parkinson's disease
Richard, I. H., Kurlan, R., & Parkinson Study Group (1997) · Neurology · doi:10.1212/wnl.49.4.1168 · Cited by 169
Prospective cohort study of impulse control disorders in Parkinson's disease
Bastiaens, J., Dorfman, B. J., Christos, P. J., & Nirenberg, M. J. (2013) · Movement Disorders · doi:10.1002/mds.25291 · Cited by 168
Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease
Weintraub, D., Chiang, C., Kim, H. M., Wilkinson, J., Marras, C., Stanislawski, B., Mamikonyan, E., & Kales, H. C. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0031 · Cited by 168
Self-citationCugusi, L., Solla, P., Serpe, R., Carzedda, T., Piras, L., Oggianu, M., Gabba, S., Di Blasio, A., Bergamin, M., Cannas, A., et al. (2015) · NeuroRehabilitation: An International, Interdisciplinary Journal · doi:10.3233/nre-151257 · Cited by 165
Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked
Ekker, M. S., Janssen, S., Seppi, K., Poewe, W. H., de Vries, N. M., Theelen, T., Nonnekes, J. H., & Bloem, B. R. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.02.014 · Cited by 161
Self-citationBlind randomized controlled study of the efficacy of cognitive training in Parkinson's disease
París, A. P., Saleta, H. G., de la Cruz Crespo Maraver, M., Silvestre, E., Freixa, M. G., Torrellas, C. P., Pont, S. A., Nadal, M. F., Garcia, S. A., Bartolomé, M. V. P., et al. (2011) · Movement Disorders · doi:10.1002/mds.23688 · Cited by 160
Manenti, R., Brambilla, M., Benussi, A., Rosini, S., Cobelli, C., Ferrari, C., Petesi, M., Orizio, I., Padovani, A., Borroni, B., et al. (2016) · Movement Disorders · doi:10.1002/mds.26561 · Cited by 160
Targeting impulsivity in Parkinson’s disease using atomoxetine
Kehagia, A. A., Housden, C. R., Regenthal, R., Barker, R. A., Müller, U., Rowe, J. B., Sahakian, B. J., & Robbins, T. W. (2014) · Brain · doi:10.1093/brain/awu117 · Cited by 154
Hauser, R. A., Isaacson, S., Lisk, J. P., Hewitt, L. A., & Rowse, G. J. (2014) · Movement Disorders · doi:10.1002/mds.26086 · Cited by 149
Sialorrhea in Parkinson's disease: A review
Chou, K. L., Evatt, M. L., Hinson, V. K., & Kompoliti, K. (2007) · Movement Disorders · doi:10.1002/mds.21646 · Cited by 149
The new definition and diagnostic criteria of Parkinson's disease
Postuma, R. B., Berg, D., Adler, C. H., Bloem, B. R., Chan, P., Deuschl, G., Gasser, T., Goetz, C. G., Halliday, G. M., Joseph, L., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00116-2 · Cited by 149
Safety of repeated sessions of transcranial direct current stimulation: A systematic review
Nikolin, S., Huggins, C., Martin, D. M., Alonzo, A., & Loo, C. K. A. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.10.020 · Cited by 149
Neikrug, A. B., Liu, L., Avanzino, J. A., Maglione, J. E., Natarajan, L., Bradley, L., Maugeri, A., Corey‐Bloom, J., Palmer, B. W., Loredo, J. S., et al. (2014) · SLEEP · doi:10.5665/sleep.3332 · Cited by 138
Guidubaldi, A., Fasano, A. A., Ialongo, T., et al. (2011) · Movement Disorders · doi:10.1002/mds.23473 · Cited by 135
Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease
Giacopo, R. D., Fasano, A. A., Quaranta, D., Marca, G. D., Bove, F., & Bentivoglio, A. R. (2012) · Movement Disorders · doi:10.1002/mds.24909 · Cited by 128
Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study
Mamikonyan, E., Xie, S. X., Melvin, E., & Weintraub, D. A. (2015) · Movement Disorders · doi:10.1002/mds.26236 · Cited by 127
Self-citationTrenkwalder, C., Chaudhuri, К. R., Martínez‐Martín, P., Rascol, O., Ehret, R., Vališ, M., Sátori, M., Krygowska‐Wajs, A., Martı́, M. J., Reimer, K., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00243-4 · Cited by 124
Chaudhuri, К. R., Rojo, J. M., Schapira, A. H. V., Brooks, D. J., Stocchi, F., Odin, P., Antonini, A., Brown, R. G., & Martínez‐Martín, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057221 · Cited by 123
Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease
Dafsari, H. S., Reddy, P., Herchenbach, C., Wawro, S., Petry‐Schmelzer, J. N., Visser-Vandewalle, V. E. R. M., Rizos, A., Silverdale, M., Ashkan, K., Samuel, M., et al. (2015) · Brain stimulation · doi:10.1016/j.brs.2015.08.005 · Cited by 121
Apomorphine‐induced penile erections in Parkinson's disease
O’Sullivan, J. D., & Hughes, A. J. (1998) · Movement Disorders · doi:10.1002/mds.870130326 · Cited by 120
Chaudhuri, К. R., Sauerbier, A., Rojo, J. M., Sethi, K. D., Schapira, A. H. V., Brown, R. G., Antonini, A., Stocchi, F., Odin, P., Bhattacharya, K., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.12.031 · Cited by 120
Psychosis in Parkinson's disease
Poewe, W. H. (2003) · Movement Disorders · doi:10.1002/mds.10567 · Cited by 119
Non‐motor Parkinson disease: new concepts and personalised management
Titova, N., & Chaudhuri, К. R. (2018) · The Medical Journal of Australia · doi:10.5694/mja17.00993 · Cited by 118
Hanagasi, H. A., Gurvit, H. I., Unsalan, P., Horozoğlu, H., Tuncer, N., Feyzioğlu, A., Günal, D. İ., Yener, G., Çakmur, R., Sahin, H. A., et al. (2011) · Movement Disorders · doi:10.1002/mds.23738 · Cited by 115
Effects of cognitive training in Parkinson's disease: A randomized controlled trial
Petrelli, A., Kaesberg, S., Barbe, M. T., Timmermann, L., Fink, G. R., Kessler, J., & Kalbe, E. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.08.023 · Cited by 114
Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease
Ondo, W. G., Kenney, C., Sullivan, K., Davidson, A., Hunter, C., Jahan, I., McCombs, A., Miller, A., & Zesiewicz, T. A. (2012) · Neurology · doi:10.1212/wnl.0b013e3182574f28 · Cited by 112
Cognitive training in Parkinson disease
Zimmermann, R., Gschwandtner, U., Benz, N., Hatz, F., Schindler, C., Taub, E., & Fuhr, P. (2014) · Neurology · doi:10.1212/wnl.0000000000000287 · Cited by 109
Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms
Eschlböck, S., Wenning, G. K., & Fanciulli, A. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1791-y · Cited by 106
Rascol, O., Zesiewicz, T., Chaudhuri, К. R., Asgharnejad, M., Surmann, E., Dohin, E., Nilius, S. M., & Bauer, L. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.678 · Cited by 105
Emotional manifestations of PD: Neurobiological basis
Castrioto, A., Thobois, S., Carnicella, S., Maillet, A., & Krack, P. (2016) · Movement Disorders · doi:10.1002/mds.26587 · Cited by 105
Yafi, F. A., Sharlip, I. D., & Becher, E. F. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.08.001 · Cited by 105
Barone, P., Santangelo, G., Morgante, F., ONOFRJ, M. C., Meco, G., Abbruzzese, G., Bonuccelli, U., Cossu, G., Pezzoli, G., Stanzione, P., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12724 · Cited by 104
Chinnapongse, R. B., Gullo, K. L., Nemeth, P. R., et al. (2011) · Movement Disorders · doi:10.1002/mds.23929 · Cited by 104
Impulse Control and Related Disorders in Parkinson's Disease
Lim, S., Evans, A. H., & Miyasaki, J. M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1444.006 · Cited by 103
Naltrexone for impulse control disorders in Parkinson disease: A placebo-controlled study
Papay, K., Xie, S. X., Stern, M., Hurtig, H. I., Siderowf, A. D., Duda, J. E., Minger, J., & Weintraub, D. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000729 · Cited by 103
Self-citationRandomized trial of cognitive speed of processing training in Parkinson disease
Edwards, J. D., Hauser, R. A., O’Connor, M. L., Valdés, E. G., Zesiewicz, T. A., & Uc, E. Y. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a823ba · Cited by 102
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic
Pondal, M., Marras, C., Miyasaki, J., Moro, E., Armstrong, M. J., Strafella, A. P., Shah, B. B., Fox, S., Prashanth, L. K., Phielipp, N., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302684 · Cited by 99
Self-citationRodrigues, T. M., Caldas, A. C., & Ferreira, J. J. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.03.002 · Cited by 99
Hauser, R. A., Hewitt, L. A., & Isaacson, S. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-130259 · Cited by 98
Neurofunctional correlates of attention rehabilitation in Parkinson’s disease: an explorative study
Cerasa, A., Gioia, M. C., Salsone, M., Donzuso, G., Chiriaco, C., Realmuto, S., Nicoletti, A. S. Q., Bellavia, G., Banco, A., D’Amelio, M., et al. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1666-z · Cited by 96
Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease
Arai, E., Arai, M., Uchiyama, T., Higuchi, Y., Aoyagi, K., Yamanaka, Y., Yamamoto, T., Nagano, O., Shiina, A., Maruoka, D., et al. (2012) · Brain · doi:10.1093/brain/aws086 · Cited by 90
Improving functional disability and cognition in Parkinson disease: Randomized controlled trial
Peña, J., Ibarretxe‐Bilbao, N., García‐Gorostiaga, I., Gómez‐Beldarrain, M. Á., Díez‐Cirarda, M., & Ojeda, N. (2014) · Neurology · doi:10.1212/wnl.0000000000001043 · Cited by 90
Randomized, Controlled Trial of Acupuncture for Fatigue in Parkinson's Disease
Kluger, B. M., Rakowski, D. R., Christian, M. K., Dong-Cedar, D. Q., Wong, B., Crawford, J., Uveges, K., Berk, J., Abaca, E., Corbin, L. W., et al. (2016) · Movement Disorders · doi:10.1002/mds.26597 · Cited by 90
Troeung, L., Egan, S. J., & Gasson, N. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-19 · Cited by 85
Leelakanok, N., Holcombe, A. L., & Schweizer, M. L. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0360-0 · Cited by 84
Makkos, A., Pál, E., Aschermann, Z., Janszky, J., Balázs, É., Takács, K., Karádi, K., Komoly, S., & Kovács, N. (2016) · Neuropsychobiology · doi:10.1159/000445296 · Cited by 83
Zesiewicz, T. A., Evatt, M. L., Vaughan, C. P., Jahan, I., Singer, C., ORDORICA, R. C., Salemi, J. L., Shaw, J., & Sullivan, K. L. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.02.025 · Cited by 81
Biundo, R., Weis, L., Fiorenzato, E., Gentile, G., Giglio, M., Schifano, R., Campo, M. C., Marcon, V., Martinez-Martin, P., Bisiacchi, P., et al. (2015) · Brain Stimulation · doi:10.1016/j.brs.2015.07.043 · Cited by 79
Pierantozzi, M., Placidi, F., Liguori, C., Albanese, M., Imbriani, P., Marciani, M. G., Mercuri, N. B., Stanzione, P., & Stefani, A. (2016) · Sleep Medicine · doi:10.1016/j.sleep.2016.01.016 · Cited by 79
Li, F., Fu, T., Tong, W., Liu, B., Li, C., Gao, Y., Wu, J.-S., Wang, X.-F., & Zhang, A. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.01.015 · Cited by 79
Rochester, M. P., Kane, A. M., Linnebur, S. A., & Fixen, D. R. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618772979 · Cited by 78
Antonini, A., Bauer, L., Dohin, E., Oertel, W. H., Rascol, O., Reichmann, H., Schmid, M., Singh, P., TOLOSA, E. S., & Chaudhuri, К. R. (2015) · European Journal of Neurology · doi:10.1111/ene.12757 · Cited by 75
Long-term Safety of Rivastigmine in Parkinson Disease Dementia
Emre, M., Poewe, W. H., Deyn, P. P. D., et al. (2014) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000010 · Cited by 74
Vouri, S. M., Kebodeaux, C. D., Stranges, P. M., & Teshome, B. F. (2016) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2016.11.006 · Cited by 72
Calleo, J. S., Amspoker, A. B., Sarwar, A. I., Kunik, M. E., Jankovic, J., Marsh, L., York, M., & Stanley, M. A. (2015) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988715588831 · Cited by 71
Dopaminergic Therapies for Non-motor Symptoms in Parkinson’s Disease
Schaeffer, E., & Berg, D. (2017) · CNS Drugs · doi:10.1007/s40263-017-0450-z · Cited by 71
The need for expanded monitoring of adverse events in behavioral health clinical trials
Peterson, A. L., Roache, J. D., Raj, J., & Young-McCaughan, S. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.10.009 · Cited by 70
Jang, W., Park, J., Shin, K. J., Kim, J., Kim, J. S., Youn, J., Cho, J. W., Oh, E., Ahn, J. Y., Oh, K., et al. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.11.015 · Cited by 69
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo‐controlled trial
Weintraub, D. A., Hauser, R. A., Elm, J. J., Pagán, F., Davis, M. D., Choudhry, A., & for the MODERATO Investigators (2016) · Movement Disorders · doi:10.1002/mds.26617 · Cited by 69
Self-citationManagement of constipation in Parkinson’s disease
Rossi, M., Merello, M., & Perez‐Lloret, S. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.997211 · Cited by 68
Self-citationPathophysiologic mechanisms in REM sleep behavior disorder
Mahowald, M. W., Schenck, C. H., & Bornemann, M. A. C. (2007) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-007-0013-7 · Cited by 66
Ondo, W. G., Shinawi, L., Davidson, A. L., & Lai, D. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.12.003 · Cited by 63
The Role of Transcranial Magnetic Stimulation in Treatment-Resistant Depression: A Review
Lee, J. C., Blumberger, D. M., Fitzgerald, P. B., Daskalakis, Z. J., & LEVINSON, A. J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803523644 · Cited by 63
Perissinotto, M. C. R., D’Ancona, C. A. L., Lúcio, A. C., Campos, R. M., & Abreu, A. (2015) · Journal of Wound Ostomy and Continence Nursing · doi:10.1097/won.0000000000000078 · Cited by 63
Sako, W., Miyazaki, Y., Izumi, Y., & Kaji, R. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306090 · Cited by 62
Effect of controlled-release levodopa on the microstructure of sleep in Parkinson’s disease
Wailke, S., Herzog, J., Witt, K., Deuschl, G., & Volkmann, J. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03213.x · Cited by 61
Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease
Fanciulli, A., Goebel, G., Metzler, B., Sprenger, F., Poewe, W. H., Wenning, G. K., & Seppi, K. (2015) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12270 · Cited by 60
Self-citationTreatment options for depression and psychosis in Parkinson's disease
Poewe, W. H., & Seppi, K. (2001) · Journal of Neurology · doi:10.1007/pl00007821 · Cited by 59
Self-citationHauser, R., Sławek, J., Barone, P., Dohin, E., Surmann, E., Asgharnejad, M., & Bauer, L. (2016) · BMC Neurology · doi:10.1186/s12883-016-0610-7 · Cited by 58
Weekly exercise does not improve fatigue levels in Parkinson's disease
Winward, C. E., Sackley, C. M., Meek, C., Izadi, H., Barker, K. L., Wade, D. T., & Dawes, H. (2011) · Movement Disorders · doi:10.1002/mds.23966 · Cited by 55
Lim, S., Tan, Z. K., Ngam, P. I., Lor, T. L., Mohamed, H., Schee, J. P., Tan, A. K., Goh, J. Y., Ooi, E., & Soh, P. C.-H. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.07.009 · Cited by 54
Oehlberg, K., Barg, F. K., Brown, G. K., Taraborelli, D., Stern, M. B., & Weintraub, D. (2008) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988708316862 · Cited by 53
Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease
Lim, T. T., Kluger, B. M., Rodriguez, R. L., Malaty, I. A., Palacio, R., Ojo, O. O., Patel, S., Gujrati, Y., Nutter, B., Swartz, C., et al. (2015) · Movement Disorders · doi:10.1002/mds.26429 · Cited by 50
Wang, F., Sun, L. Z., Zhang, X.-Z., Jia, J., Liu, Z., Huang, X., Yu, S., Zuo, L.-J., Cao, C.-J., Wang, X., et al. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/692795 · Cited by 48
Ziprasidone Versus Clozapine in the Treatment of Psychotic Symptoms in Parkinson Disease
Pintor, L., Valldeoriola, F., Baillés, E., et al. (2012) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31824d5115 · Cited by 47
Hawkins, T., & Berman, B. D. (2017) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000342 · Cited by 47
Christie, J. A., Shroff, S. R., Shahnavaz, N., Carter, L. A., Harrison, M., Dietz-Lindo, K. A., Hanfelt, J., & Srinivasan, S. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.531 · Cited by 43
Morlion, B. J., Mueller‐Lissner, S., Vellucci, R., Leppert, W., Coffin, B., Dickerson, S., & O’Brien, T. (2017) · Pain Practice · doi:10.1111/papr.12646 · Cited by 42
Perez‐Lloret, S., Ñano, G., Carrosella, A., Gamzu, E. R., & Merello, M. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.05.021 · Cited by 40
Self-citationLiu, H., Chen, L., Zhang, Z., Geng, G., Chen, W., Dong, H., Chen, L., Zhan, S., & Li, T. (2017) · Acupuncture in Medicine · doi:10.1136/acupmed-2016-011342 · Cited by 40
Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale
Manolis, T. A., Manolis, A. S., & Manolis, A. S. (2018) · Angiology · doi:10.1177/0003319718780145 · Cited by 39
Hauser, R. A., Isaacson, S., & Clinch, T. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.08.010 · Cited by 38
Eggert, K. M., Öhlwein, C., Kassubek, J., Wolz, M., Kupsch, A. R., Ceballos-Baumann, A., Ehret, R., Polzer, U., Klostermann, F., Schwarz, J., et al. (2014) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000041 · Cited by 38
Management of impulse control disorders with deep brain stimulation: A double-edged sword
Kasemsuk, C., Oyama, G., & Hattori, N. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.01.019 · Cited by 37
Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine
Moreno, G. J., Gandhi, R., Lessig, S. L., Wright, B. A., Litvan, I., & Nahab, F. B. (2018) · Neurology · doi:10.1212/wnl.0000000000006396 · Cited by 37
(2002) · Movement Disorders · doi:10.1002/mds.5555 · Cited by 37
Antipsychotic Use and Physical Morbidity in Parkinson Disease
Weintraub, D. A., Chiang, C., Kim, H. M., Wilkinson, J. R., Marras, C., Stanislawski, B., Mamikonyan, E., & Kales, H. C. (2017) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2017.01.076 · Cited by 32
Self-citationA randomized, double‐blind trial of transcranial electrostimulation in early Parkinson's disease
Shill, H. A., Obradov, S., Katsnelson, Y., & Pizinger, R. (2011) · Movement Disorders · doi:10.1002/mds.23591 · Cited by 30
Guided self-help for the management of worry in parkinson's disease: A pilot study
Lawson, R. A., Millar, D., Brown, R. G., & Burn, D. J. (2013) · Journal of Parkinson's Disease · doi:10.3233/jpd-120156 · Cited by 29
Homotaurine in Parkinson’s disease
Ricciardi, L., Nigris, F. D., Specchia, A., & Fasano, A. A. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2201-6 · Cited by 29
Sildenafil in the Treatment of Erectile Dysfunction in Parkinson's Disease
Bernard, B. A., Metman, L. V., Levine, L. A., Ouyang, B., Leurgans, S. E., & Goetz, C. G. (2016) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12456 · Cited by 28
Nonpharmacologic Interventions for Agitation and Aggression in Dementia
Brasure, M., Jutkowitz, E., Fuchs, E. L., et al. (2015) · Europe PMC (PubMed Central) · doi:10.7301/z03n21b6 · Cited by 27
Sialorrhea in Patients with Parkinson's Disease: Safety and Administration of Botulinum Neurotoxin
Egevad, G., Petkova, V. Y., & Vilholm, O. J. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-140379 · Cited by 26
Lesenskyj, A. M., Samples, M. P., Farmer, J., & Maxwell, C. R. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0113-0 · Cited by 26
Guerriero, F., Roberto, A., Greco, T., Sgarlata, C. S., Rollone, M., & Corli, O. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s106025 · Cited by 25
Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center
Patel, S., Garcia, X., Mohammad, M. E., Yu, X., Vlastaris, K., O'Donnell, K., Sutton, K., & Fernandez, H. H. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.06.022 · Cited by 22
Hadinia, A., Meyer, A., Bruegger, V., Hatz, F., Nowak, K., Taub, E., Nyberg, E., Stieglitz, R.-D., Fuhr, P., & Gschwandtner, U. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2016.01975 · Cited by 20
Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia
Frakey, L. L., & Friedman, J. H. (2016) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.15050118 · Cited by 20
Does abdominal massage relieve constipation?
McClurg, D., & Lowe-Strong, A. S. (2011) · PubMed · Cited by 18
Thakur, D., Dickerson, S., Bhutani, M. K., & Junor, R. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.12.001 · Cited by 17
The Evidence Based Medicine Workbook: Critical Appraisal for Clinical Problem Solving
Carey, M. J. (1998) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(98)70124-6 · Cited by 17
Cash, T. V., & Lageman, S. K. (2015) · BMC Psychology · doi:10.1186/s40359-015-0101-4 · Cited by 15
Oxycodone/Naloxone Prolonged Release: A Review in Severe Chronic Pain
Kim, E. S. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0593-1 · Cited by 13
Pieper, D., & Mathes, T. (2017) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2016-110609 · Cited by 10
Kunisaki, K. M., Khalil, W., Koffel, E., Pfannes, L. V., Koeller, E., MacDonald, R. H., Greer, N. L., & Wilt, T. J. (2016) · Europe PMC (PubMed Central) · Cited by 5
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Parkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Ray Chaudhuri, K., & Weintraub, D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,371
Self-citationThe neuropsychiatry of Parkinson's disease: advances and challenges
Weintraub, D., Aarsland, D., Chaudhuri, K. R., Dobkin, R. D., Leentjens, A. F., Rodriguez-Violante, M., & Schrag, A. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00330-6 · Cited by 450
Self-citationLevodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
Jost, S. T., Kaldenbach, M., Antonini, A., Martinez‐Martin, P., Timmermann, L., Odin, P., Katzenschlager, R., Borgohain, R., Fasano, A., Stocchi, F., et al. (2023) · Movement Disorders · doi:10.1002/mds.29410 · Cited by 389
Self-citation
Metadata
- Authors
- Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., Sampaio, C., & and the collaborators of the Parkinson's Disease Update on Non‐Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence‐Based Medicine Committee
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2019-01-17
- Volume
- 34
- Issue
- 2
- Pages
- 180-198
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2908548900
- Cited by
- 1,007
- References
- 159
- FWCI
- 71.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.